Third Quarter 2015 Financial Results

BioLight today reported operational and financial results for the third quarter ended September 30, 2015.

Operational Highlights:

  • Reported first IOPtiMate™ System sales and additional distribution agreements, both in new territories.
  • Completed enrollment into the second U.S. clinical study in which TeaRx’s effectiveness is being assessed in tears …

    Continue reading

Partnership with Axella Research for CellDetect® Non-Invasive Test for Monitoring Recurrence of Bladder Cancer

BioLight announced today that its cancer diagnostics subsidiary, Micromedic Technologies, has entered into a Collaboration Agreement with Axella Research LLC, to advance the clinical and regulatory efforts required to commercialize the CellDetect® non-invasive diagnostic test for the monitoring of bladder cancer recurrence in the United States.

Link to …

Continue reading

Joint Investment in IOPtima Subsidiary

BioLight announced today that it has entered into a joint financing agreement with two Asia-based venture capital firms, pursuant to which BioLight and the New Investors will make a direct equity investment in BioLight’s  IOPtima Ltd. subsidiary via a private placement. The financing will help IOPtima to continue the global …

Continue reading

Second Quarter 2015 Financial Results

BioLight today reported operational and financial results for the second quarter ended June 30, 2015.

Operational Highlights:

  • Completed an upsized private investment and signed a strategic partnership with Rock-One International Holdings Ltd. designed to help BioLight maximize its presence within China, the second largest healthcare market in the world after the …

    Continue reading

Positive Clinical Study Results for Identifying New Genetic Markers to Predict Risk of Developing BRONJ

BioLight today announced that its cancer diagnostics subsidiary, Micromedic Technologies, has identified several new genetic markers with high potential to predict necrosis of the jawbone in patients treated with bisphosphonate drugs and was able to repeat findings from a previous study for one significant marker in a larger and more diversified group …

Continue reading